ABSTRACT
Objective To investigate the efficacy and safety of clopidogrel hydrogen sulfate plus nimodipine in treating transient cerebral ischemic attack.Methods A total of 159 outpatients and inpatients with transient cerebral ischemic attack in the neurosurgery department and the neurology outpatient department of our hospital from January 1,2012 to September 1,2016 were divided into 3 groups.The group A(43 cases) orally took clopidogrel hydrogen sulfate plus aspirin;the group B (51 cases) treated with oral clopidogrel hydrogen sulfate plus nimodipine;the group C(65 cases) was treated with clopidogrel hydrogen sulfate plus nimotop.The curative effects were observed in 3 groups.The differences of PT.APTT,FIB and PLT in 3 groups were compared between before and after treatment.Results The total effective rate of the group A and C was significantly better than that of the group B(P0.05);the effect of the group B and group C on coagulation was superior to that of the group A(P<0.05).The three group had no severe bleeding events(cerebral bleeding,etc.),the difference was statistically significant.Conclusion Clopidogrel hydrogen sulfate combined with nimotop can significantly reduce the frequency of transient cerebral ischemic attack,has little influence on the coagulation indicators,and is safe and effective.
ABSTRACT
Objective To analyze and discuss the clinical efficacy of clopidogrel bisulfate combined with aspirin in the treatment of unstable angina pectoris. Methods 86 cases of unstable angina pectoris treated in my hospital from July 2015 to September 2016 were taken as the research object, randomly divided into two groups, with 43cases in each group. The observation group received clopidogrel combined with aspirin therapy; The control group received aspirin treatment alone. The clinical efficacy of the two groups was compared. Results There was no significant difference in the incidence of adverse reactions between the observation group and the control group (9.30% vs 6.98%), but the total effective rate of the clinical observation group was significantly higher (93.02% vs 76.74%, P<0.05). Conclusion Clopidogrel hydrogen sulfate combined with aspirin in the treatment of unstable angina pectoris is effective, safe and reliable..
ABSTRACT
Objective To analyze and discuss the clinical efficacy of clopidogrel bisulfate combined with aspirin in the treatment of unstable angina pectoris. Methods 86 cases of unstable angina pectoris treated in my hospital from July 2015 to September 2016 were taken as the research object, randomly divided into two groups, with 43cases in each group. The observation group received clopidogrel combined with aspirin therapy; The control group received aspirin treatment alone. The clinical efficacy of the two groups was compared. Results There was no significant difference in the incidence of adverse reactions between the observation group and the control group (9.30% vs 6.98%), but the total effective rate of the clinical observation group was significantly higher (93.02% vs 76.74%, P<0.05). Conclusion Clopidogrel hydrogen sulfate combined with aspirin in the treatment of unstable angina pectoris is effective, safe and reliable..
ABSTRACT
Objective To evaluate the feasibility of application of single and dual antiplatelet aggregation therapy in high sensitive C-reactive protein (hs-CRP) level in patients with angina pectoris. Methods Ninety-six hospitalized patients with angina 6~48 h (hs-CRP0.05). There were no significant differences in events of composite end points in patients after treatment between two groups (P > 0.05). Conclusion For angina pectoris patients with hs-CRP<2 mg/L, the risk of cardiovascular events is relatively little. There is no obvious difference in curative effect between single and dual antiplatelet aggreration therapies.
ABSTRACT
Objective To establish a high performance liquid chromatography(HPLC) method for quantitative determination of S-clopidogrel and its related substance R-clopidogrel in clopidogrel tablets, and to compare their contents between clopidogrel tablets produced by three different manufacturers. Methods An ULTRON ES-OVM column (4.6 mm × 150 mm,5 μm) was used in this study. The mobile phase consisted of a mixture of acetonitrile and 0.01 mol/L potassium dihydrogen phosphate solution (20:80). The flow-rate was 1 mL/min, with the column temperature being 17°C and the UV detection wave lenth being 220 nm. Results S-clopidogrel and its related substance R-clopidogrel were in good linear relationship within 50-117 mg/L and 1.52-30.04 mg/L, respectively (both r=0.999 8). The precision of our method was satisfactory and the average recoveries were 99.7% and 98.8%, respectively. The test solution remained stable for 12 h. S-clopidogrel and R-clopidogrel in clopidogrel tablets produced by three manufacturers were in line with the quality requirements of pharmacopoeia. Conclusion Our method is accurate and has good specificity. It can be used for the quality control of clopidogrel tablets.